Format

Send to

Choose Destination
Br J Haematol. 2002 Jun;117(3):623-5.

Low concentrations of STI571 in the cerebrospinal fluid: a case report.

Author information

1
Abteilung für Hämatologie & Onkologie, Universitätsklinik Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. andreas.petzer@uibk.ac.at

Abstract

We report a 53-year-old man with lymphoid blast crisis of Ph+ chronic myeloid leukaemia who was treated with STI571, a selective inhibitor of the enzymatic activity of BCR-ABL. He responded excellently to STI571 (600 mg/d), obtaining a complete cytogenetic remission after 3 months of therapy. Although remission in the bone marrow was sustained, the patient developed an isolated central nervous system relapse. Subsequent analyses of STI571 concentrations in the cerebrospinal fluid (CSF) revealed 2-log lower CSF levels of STI571 than corresponding plasma levels. These are the first data demonstrating a low penetration of orally administered STI571 into the CSF in humans.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center